{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:11Z","timestamp":1788798431735,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06592"],"award-info":[{"award-number":["21K06592"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K18551"],"award-info":[{"award-number":["19K18551"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008731","name":"Nakatomi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00262-021-03032-0","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T14:03:15Z","timestamp":1628690595000},"page":"727-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of HLA genotype on intravesical recurrence after bacillus Calmette\u2013Gu\u00e9rin therapy for non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"71","author":[{"given":"Mizuki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiyoshi","family":"Tanegashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ario","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Numakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyasu","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"issue":"3","key":"3032_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Hern\u00e1ndez V, Kaasinen E, Palou J, Roupr\u00eat M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"issue":"3","key":"3032_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"issue":"1","key":"3032_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/01.ju.0000039680.90768.b3","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169(1):90\u201395. https:\/\/doi.org\/10.1097\/01.ju.0000039680.90768.b3","journal-title":"J Urol"},{"issue":"3","key":"3032_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.eururo.2005.11.010","volume":"49","author":"JA Witjes","year":"2006","unstructured":"Witjes JA, Melissen DO, Kiemeney LA (2006) Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. Eur Urol 49(3):478\u2013484. https:\/\/doi.org\/10.1016\/j.eururo.2005.11.010","journal-title":"Eur Urol"},{"issue":"1","key":"3032_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cas.12075","volume":"104","author":"K Kawai","year":"2013","unstructured":"Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H (2013) Bacillus Calmette\u2013Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104(1):22\u201327. https:\/\/doi.org\/10.1111\/cas.12075","journal-title":"Cancer Sci"},{"issue":"1","key":"3032_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-017-0271-0","volume":"5","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O\u2019Donnell MA, O\u2019Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE (2017) Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):68. https:\/\/doi.org\/10.1186\/s40425-017-0271-0","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3032_CR7","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi\u00f1eiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Munta\u00f1ola P, Gimeno A, Blas M, Martinez-Pi\u00f1eiro JA (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: the CUETO scoring model. J Urol 182(5):2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016","journal-title":"J Urol"},{"issue":"2","key":"3032_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/iji.12517","volume":"48","author":"M Ivanova","year":"2021","unstructured":"Ivanova M, Shivarov V (2021) HLA genotyping meets response to immune checkpoint inhibitors prediction: a story just started. Int J Immunogenet 48(2):193\u2013200. https:\/\/doi.org\/10.1111\/iji.12517","journal-title":"Int J Immunogenet"},{"key":"3032_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2172-9-1","volume":"9","author":"J Sidney","year":"2008","unstructured":"Sidney J, Peters B, Frahm N, Brander C, Sette A (2008) HLA class I supertypes: a revised and updated classification. BMC Immunol 9:1. https:\/\/doi.org\/10.1186\/1471-2172-9-1","journal-title":"BMC Immunol"},{"issue":"6375","key":"3032_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582\u2013587. https:\/\/doi.org\/10.1126\/science.aao4572","journal-title":"Science"},{"issue":"11","key":"3032_CR11","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","volume":"25","author":"D Chowell","year":"2019","unstructured":"Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, Morris LGT, Riaz N, Lenz TL, Chan TA (2019) Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med 25(11):1715\u20131720. https:\/\/doi.org\/10.1038\/s41591-019-0639-4","journal-title":"Nat Med"},{"issue":"3","key":"3032_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/1078-0432.CCR-18-1940","volume":"25","author":"C Richard","year":"2019","unstructured":"Richard C, Fumet JD, Chevrier S, Derang\u00e8re V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F (2019) Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients. Clin Cancer Res 25(3):957\u2013966. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1940","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3032_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000733","volume":"8","author":"P Correale","year":"2020","unstructured":"Correale P, Saladino RE, Giannarelli D, Giannicola R, Agostino R, Staropoli N, Strangio A, Del Giudice T, Nardone V, Altomonte M, Pastina P, Tini P, Falzea AC, Imbesi N, Arcati V, Romeo G, Caracciolo D, Luce A, Caraglia M, Giordano A, Pirtoli L, Necas A, Amler E, Barbieri V, Tassone P, Tagliaferri P (2020) Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1\/PD-L1 immune checkpoint blockade. J Immunother Cancer 8(1):e000733. https:\/\/doi.org\/10.1136\/jitc-2020-000733","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3032_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001620","volume":"8","author":"A Abed","year":"2020","unstructured":"Abed A, Calapre L, Lo J, Correia S, Bowyer S, Chopra A, Watson M, Khattak MA, Millward M, Gray ES (2020) Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. J Immunother Cancer 8(2):e001620. https:\/\/doi.org\/10.1136\/jitc-2020-001620","journal-title":"J Immunother Cancer"},{"key":"3032_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bbacli.2015.06.002","volume":"4","author":"A Kiselyov","year":"2015","unstructured":"Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V (2015) Treatment of non-muscle invasive bladder cancer with Bacillus Calmette\u2013Guerin (BCG): biological markers and simulation studies. BBA Clin 4:27\u201334. https:\/\/doi.org\/10.1016\/j.bbacli.2015.06.002","journal-title":"BBA Clin"},{"issue":"7","key":"3032_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00262-020-02533-8","volume":"69","author":"M Shiota","year":"2020","unstructured":"Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, Matsuyama H, Eto M (2020) Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette\u2013Gu\u00e9rin therapy for non-muscle invasive bladder cancer. Cancer Immunol Immunother 69(7):1155\u20131163. https:\/\/doi.org\/10.1007\/s00262-020-02533-8","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"3032_CR17","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/ijc.25850","volume":"129","author":"N Kawata","year":"2011","unstructured":"Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, Satoh S, Mitobe Y, Narita S, Habuchi T (2011) Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer 129(8):1872\u20131880. https:\/\/doi.org\/10.1002\/ijc.25850","journal-title":"Int J Cancer"},{"key":"3032_CR18","doi-asserted-by":"publisher","unstructured":"Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22(12):1435\u201348. https:\/\/doi.org\/10.1097\/00000478-199812000-00001","DOI":"10.1097\/00000478-199812000-00001"},{"key":"3032_CR19","volume-title":"TNM classification of malignant tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. John Wiley & Sons Inc., Hoboken","edition":"7"},{"key":"3032_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105881","volume":"76","author":"N Fujiyama","year":"2019","unstructured":"Fujiyama N, Satoh S, Saito M, Numakura K, Inoue T, Yamamoto R, Saito T, Nara T, Kanda S, Narita S, Kagaya H, Miura M, Habuchi T (2019) Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation. Int Immunopharmacol 76:105881. https:\/\/doi.org\/10.1016\/j.intimp.2019.105881","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"3032_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/tpj.2015.4","volume":"15","author":"SS Khor","year":"2015","unstructured":"Khor SS, Yang W, Kawashima M, Kamitsuji S, Zheng X, Nishida N, Sawai H, Toyoda H, Miyagawa T, Honda M, Kamatani N, Tokunaga K (2015) High-accuracy imputation for HLA class I and II genes based on high-resolution SNP data of population-specific references. Pharmacogenom J 15(6):530\u2013537. https:\/\/doi.org\/10.1038\/tpj.2015.4","journal-title":"Pharmacogenom J"},{"issue":"9","key":"3032_CR22","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/molbev\/msy116","volume":"35","author":"F Pierini","year":"2018","unstructured":"Pierini F, Lenz TL (2018) Divergent allele advantage at human MHC genes: signatures of past and ongoing selection. Mol Biol Evol 35(9):2145\u20132158. https:\/\/doi.org\/10.1093\/molbev\/msy116","journal-title":"Mol Biol Evol"},{"issue":"4154","key":"3032_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.185.4154.862","volume":"185","author":"R Grantham","year":"1974","unstructured":"Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185(4154):862\u2013864. https:\/\/doi.org\/10.1126\/science.185.4154.862","journal-title":"Science"},{"issue":"5","key":"3032_CR24","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/nar\/gkh340","volume":"32","author":"RC Edgar","year":"2004","unstructured":"Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32(5):1792\u20131797. https:\/\/doi.org\/10.1093\/nar\/gkh340","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"3032_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41588-018-0167-z","volume":"50","author":"L Sundaram","year":"2018","unstructured":"Sundaram L, Gao H, Padigepati SR, McRae JF, Li Y, Kosmicki JA, Fritzilas N, Hakenberg J, Dutta A, Shon J, Xu J, Batzoglou S, Li X, Farh KK (2018) Predicting the clinical impact of human mutation with deep neural networks. Nat Genet 50(8):1161\u20131170. https:\/\/doi.org\/10.1038\/s41588-018-0167-z","journal-title":"Nat Genet"},{"issue":"4","key":"3032_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361\u2013387. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19960229)15:4%3c361::AID-SIM168%3e3.0.CO;2-4","journal-title":"Stat Med"},{"key":"3032_CR27","doi-asserted-by":"publisher","unstructured":"Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group (2021) Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Sci [Epub ahead of print]. https:\/\/doi.org\/10.1111\/cas.15038","DOI":"10.1111\/cas.15038"},{"issue":"15","key":"3032_CR28","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/1078-0432.CCR-06-0595","volume":"12","author":"H Kitamura","year":"2006","unstructured":"Kitamura H, Torigoe T, Honma I, Sato E, Asanuma H, Hirohashi Y, Sato N, Tsukamoto T (2006) Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer. Clin Cancer Res 12(15):4641\u20134644. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0595","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3032_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/ijc.25733","volume":"129","author":"R Carretero","year":"2011","unstructured":"Carretero R, Cabrera T, Gil H, Saenz-Lopez P, Maleno I, Aptsiauri N, Cozar JM, Garrido F (2011) Bacillus Calmette\u2013Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer 129(4):839\u2013846. https:\/\/doi.org\/10.1002\/ijc.25733","journal-title":"Int J Cancer"},{"issue":"5","key":"3032_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00262-020-02506-x","volume":"69","author":"DP Hurkmans","year":"2020","unstructured":"Hurkmans DP, Kuipers ME, Smit J, van Marion R, Mathijssen RHJ, Postmus PE, Hiemstra PS, Aerts JGJV, von der Th\u00fcsen JH, van der Burg SH (2020) Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients. Cancer Immunol Immunother 69(5):771\u2013777. https:\/\/doi.org\/10.1007\/s00262-020-02506-x","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"3032_CR31","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2020.04.004","volume":"31","author":"JH Shim","year":"2020","unstructured":"Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH (2020) HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann Oncol 31(7):902\u2013911. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.004","journal-title":"Ann Oncol"},{"issue":"5258","key":"3032_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1126\/science.272.5258.67","volume":"272","author":"P Parham","year":"1996","unstructured":"Parham P, Ohta T (1996) Population biology of antigen presentation by MHC class I molecules. Science 272(5258):67\u201374. https:\/\/doi.org\/10.1126\/science.272.5258.67","journal-title":"Science"},{"issue":"6","key":"3032_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067016","volume":"8","author":"DM Lewinsohn","year":"2013","unstructured":"Lewinsohn DM, Swarbrick GM, Cansler ME, Null MD, Rajaraman V, Frieder MM, Sherman DR, McWeeney S, Lewinsohn DA (2013) Human Mycobacterium tuberculosis CD8 T Cell Antigens\/Epitopes Identified by a Proteomic Peptide Library. PLoS ONE 8(6):e67016. https:\/\/doi.org\/10.1371\/journal.pone.0067016","journal-title":"PLoS ONE"},{"issue":"3","key":"3032_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.urolonc.2017.12.020","volume":"36","author":"N Mukherjee","year":"2018","unstructured":"Mukherjee N, Svatek RS, Mansour AM (2018) Role of immunotherapy in bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer. Urol Oncol 36(3):103\u2013108. https:\/\/doi.org\/10.1016\/j.urolonc.2017.12.020","journal-title":"Urol Oncol"},{"key":"3032_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.intimp.2016.03.007","volume":"35","author":"A Takeuchi","year":"2016","unstructured":"Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Takahashi R, Yokomizo A, Ohara N, Yoshikai Y (2016) Antitumor activity of recombinant Bacille Calmette\u2013Gu\u00e9rin secreting interleukin-15-Ag85B fusion protein against bladder cancer. Int Immunopharmacol 35:327\u2013331. https:\/\/doi.org\/10.1016\/j.intimp.2016.03.007","journal-title":"Int Immunopharmacol"},{"issue":"1\u20132","key":"3032_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132):48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033","journal-title":"Cell"},{"issue":"11","key":"3032_CR37","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, Stevens J, Lane WJ, Dellagatta JL, Steelman S, Sougnez C, Cibulskis K, Kiezun A, Hacohen N, Brusic V, Wu CJ, Getz G (2015) Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 33(11):1152\u20131158. https:\/\/doi.org\/10.1038\/nbt.3344","journal-title":"Nat Biotechnol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03032-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T16:11:28Z","timestamp":1645114288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03032-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03032-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"3 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shintaro Narita received honoraria from Janssen Pharmaceutical, Bayer Yakuhin, AstraZeneca, Takeda Pharmaceutical, Sanofi, and Astellas Pharma. Tomonori Habuchi received honoraria from Janssen Pharmaceutical, Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, AstraZeneca, Sanofi, and Bayer Yakuhin, and research funding support from Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Sanofi, and Bayer Yakuhin. Masatoshi Eto received honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, MSD, and Merck Biopharma, and research funding support from Sanofi, Bayer Yakuhin, Astellas Pharma., Ono Pharmaceutical., and Takeda Pharmaceutical. Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, and Astellas Pharma, and research funding support from Daiichi Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted under review board at Kyushu University (727-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}